Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Deep Vein Thrombosis (DVT) Prevention in Total Hip Replacement: Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH)

Study:

Deep Vein Thrombosis (DVT) Prevention in Total Hip Replacement: Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH)

Rationale:

n/a

Purpose:

Evaluation of the safety and effectiveness of ActiveCare+SFT CECT device +/- baby dose aspirin (81 mg QD) for lowering the potential risk for bleeding and of DVT during and after THA surgery in comparison with LMWH.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Major Bleeding
Venous Thrombosis (DVT)
Pulmonary Embolism (PE)
Device: ActiveCare+SFT
Drug: Lovenox
N/A

Verified by Medical Compression Systems February, 2010

Sponsored by: Medical Compression Systems
Information provided by: Medical Compression Systems
ClinicalTrials.gov identifier: NCT00358735

Study Type: Interventional

Study Design: Allocation: Randomized, Control: Active Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention

Cleveland Clinic
Cleveland, Ohio 44195
United States

Clifford W Colwell, M.D., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site